DEVELOPMENT OF A CORTICOSTEROID-BASED FORMULATION ASSOCIATED WITH ANTIBIOTICS (Q4195801): Difference between revisions
Jump to navigation
Jump to search
(Changed label, description and/or aliases in en: Setting new description) |
(Changed label, description and/or aliases in en, and other parts: Adding English translations) |
||||||||||||||
| label / en | label / en | ||||||||||||||
DEVELOPMENT OF A CORTICOSTEROID-BASED FORMULATION ASSOCIATED WITH ANTIBIOTICS | |||||||||||||||
| Property / summary | |||||||||||||||
THE COLLABORATION PROJECT IS BASED ON THE CHARACTERISATION OF SEMI-SOLID FORMULATIONS CONTAINING GENTAMICIN SULPHATE AND BETAMETHASONE DIPROPIONATE FOR TOPICAL USE. The FORMULATIONS WILL BE DEVELOPED BY DELIM COSMETICS & PHARMA S.R.L. and ANALISED by the University of PARMA, the one who can be as a COLLABORATOR DURING ALL the steps of the CITED PROJECT. Each OF THE FORMULATIONS DEVELOPED BY DELIM COSMETICS & PHARMA S.R.L. will present COMPOSITIONS DIFFERENT WITH THE OBJECTIVE TO PROVIDE TO THE COMPANY A NEW PRODUCTS RESPECTED TO THE FORMULATIONS IN TRADE (ES. DIPROGENTA®) THESE INNOVATIONS ARE REFLECTED IN A DECREASE IN SIDE EFFECTS AND AN INCREASE IN EFFICACIA.THE PROJECT WILL BE ARTICULATED ACCORDING TO THE PHASES AND TIMES OF REALISATION INDICATED. THE TOTAL TIME FORESEEN FOR THE REALISATION OF THE ENTIRE COLLABORATION IS 9 MONTHS, DURING WHICH TWO OR MORE PHASES OF THE PROJECT CAN OVERLAP. (English) | |||||||||||||||
| Property / summary: THE COLLABORATION PROJECT IS BASED ON THE CHARACTERISATION OF SEMI-SOLID FORMULATIONS CONTAINING GENTAMICIN SULPHATE AND BETAMETHASONE DIPROPIONATE FOR TOPICAL USE. The FORMULATIONS WILL BE DEVELOPED BY DELIM COSMETICS & PHARMA S.R.L. and ANALISED by the University of PARMA, the one who can be as a COLLABORATOR DURING ALL the steps of the CITED PROJECT. Each OF THE FORMULATIONS DEVELOPED BY DELIM COSMETICS & PHARMA S.R.L. will present COMPOSITIONS DIFFERENT WITH THE OBJECTIVE TO PROVIDE TO THE COMPANY A NEW PRODUCTS RESPECTED TO THE FORMULATIONS IN TRADE (ES. DIPROGENTA®) THESE INNOVATIONS ARE REFLECTED IN A DECREASE IN SIDE EFFECTS AND AN INCREASE IN EFFICACIA.THE PROJECT WILL BE ARTICULATED ACCORDING TO THE PHASES AND TIMES OF REALISATION INDICATED. THE TOTAL TIME FORESEEN FOR THE REALISATION OF THE ENTIRE COLLABORATION IS 9 MONTHS, DURING WHICH TWO OR MORE PHASES OF THE PROJECT CAN OVERLAP. (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: THE COLLABORATION PROJECT IS BASED ON THE CHARACTERISATION OF SEMI-SOLID FORMULATIONS CONTAINING GENTAMICIN SULPHATE AND BETAMETHASONE DIPROPIONATE FOR TOPICAL USE. The FORMULATIONS WILL BE DEVELOPED BY DELIM COSMETICS & PHARMA S.R.L. and ANALISED by the University of PARMA, the one who can be as a COLLABORATOR DURING ALL the steps of the CITED PROJECT. Each OF THE FORMULATIONS DEVELOPED BY DELIM COSMETICS & PHARMA S.R.L. will present COMPOSITIONS DIFFERENT WITH THE OBJECTIVE TO PROVIDE TO THE COMPANY A NEW PRODUCTS RESPECTED TO THE FORMULATIONS IN TRADE (ES. DIPROGENTA®) THESE INNOVATIONS ARE REFLECTED IN A DECREASE IN SIDE EFFECTS AND AN INCREASE IN EFFICACIA.THE PROJECT WILL BE ARTICULATED ACCORDING TO THE PHASES AND TIMES OF REALISATION INDICATED. THE TOTAL TIME FORESEEN FOR THE REALISATION OF THE ENTIRE COLLABORATION IS 9 MONTHS, DURING WHICH TWO OR MORE PHASES OF THE PROJECT CAN OVERLAP. (English) / qualifier | |||||||||||||||
point in time: 31 January 2022
| |||||||||||||||
Revision as of 19:22, 31 January 2022
Project Q4195801 in Italy
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | DEVELOPMENT OF A CORTICOSTEROID-BASED FORMULATION ASSOCIATED WITH ANTIBIOTICS |
Project Q4195801 in Italy |
Statements
12,500.0 Euro
0 references
25,000.0 Euro
0 references
50.0 percent
0 references
DELIM COSMETICS & PHARMA SRL
0 references
IL PROGETTO DI COLLABORAZIONE SI BASA SULLA CARATTERIZZAZIONE DI FORMULAZIONI SEMISOLIDE CONTENENTI GENTAMICINA SOLFATO E BETAMETASONE DIPROPIONATO PER USO TOPICO. LE FORMULAZIONI SARANNO SVILUPPATE DA DELIM COSMETICS & PHARMA S.R.L. ED ANALIZZATE DALL UNIVERSITà DI PARMA, LA QUALE SI PONE COME ENTE COLLABORATORE DURANTE TUTTE LE FASI DEL PROGETTO CITATO. OGNUNA DELLE FORMULAZIONI SVILUPPATE DA DELIM COSMETICS & PHARMA S.R.L. PRESENTERà COMPOSIZIONI DIFFERENTI CON L OBIETTIVO DI FORNIRE AL PAZIENTE UN PRODOTTO INNOVATIVO RISPETTO ALLE FORMULAZIONI GIà PRESENTI IN COMMERCIO (ES. DIPROGENTA®) TALI INNOVAZIONI TROVANO RISCONTRO IN UNA DIMINUZIONE DEGLI EFFETTI COLLATERALI E AD UN AUMENTO DELL EFFICACIA.IL PROGETTO SARà ARTICOLATO SECONDO LE FASI E TEMPI DI REALIZZAZIONE INDICATI. IL TEMPO TOTALE PREVISTO PER LA REALIZZAZIONE DELL INTERA COLLABORAZIONE CORRISPONDE A 9 MESI, DURANTE I QUALI DUE O PIù FASI DEL PROGETTO SI POTRANNO SOVRAPPORRE. (Italian)
0 references
THE COLLABORATION PROJECT IS BASED ON THE CHARACTERISATION OF SEMI-SOLID FORMULATIONS CONTAINING GENTAMICIN SULPHATE AND BETAMETHASONE DIPROPIONATE FOR TOPICAL USE. The FORMULATIONS WILL BE DEVELOPED BY DELIM COSMETICS & PHARMA S.R.L. and ANALISED by the University of PARMA, the one who can be as a COLLABORATOR DURING ALL the steps of the CITED PROJECT. Each OF THE FORMULATIONS DEVELOPED BY DELIM COSMETICS & PHARMA S.R.L. will present COMPOSITIONS DIFFERENT WITH THE OBJECTIVE TO PROVIDE TO THE COMPANY A NEW PRODUCTS RESPECTED TO THE FORMULATIONS IN TRADE (ES. DIPROGENTA®) THESE INNOVATIONS ARE REFLECTED IN A DECREASE IN SIDE EFFECTS AND AN INCREASE IN EFFICACIA.THE PROJECT WILL BE ARTICULATED ACCORDING TO THE PHASES AND TIMES OF REALISATION INDICATED. THE TOTAL TIME FORESEEN FOR THE REALISATION OF THE ENTIRE COLLABORATION IS 9 MONTHS, DURING WHICH TWO OR MORE PHASES OF THE PROJECT CAN OVERLAP. (English)
31 January 2022
0 references
MILANO
0 references